|
ERBB4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.30219999625336E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
2.84759993363082E-10 |
| Stage1-vs-Stage2 |
4.017600E-01 |
| Stage1-vs-Stage3 |
2.731400E-01 |
| Stage1-vs-Stage4 |
5.342400E-01 |
| Stage2-vs-Stage3 |
1.672620E-01 |
| Stage2-vs-Stage4 |
3.174400E-01 |
| Stage3-vs-Stage4 |
8.919200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.17879999999671E-05 |
| Normal-vs-Asian |
1.99450012061675E-10 |
| Caucasian-vs-AfricanAmerican |
1.214040E-01 |
| Caucasian-vs-Asian |
2.768800E-01 |
| AfricanAmerican-vs-Asian |
5.012200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.99200722162641E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.041600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
9.76996261670138E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62947433324234E-12 |
| Normal-vs-Age(81-100Yrs) |
8.555000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.583800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.483600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.536800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.107600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.686600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.338200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.16024983959551E-12 |
| Classical-VS-Follicular |
8.856000E-03 |
| Classical-VS-Other |
6.343600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.6388000107811E-09 |
| Tall-VS-Other |
1.978000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.481700E-02 |
| Follicular-VS-Normal |
6.16500000050202E-07 |
| Other-VS-Normal |
1.417330E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
1.92335036786062E-12 |
| N0-vs-N1 |
3.822200E-01 |
|
|
